AVP and COVID-19: Many studies have shown that hyponatremia is associated with complications and mortality in COVID-19 patients 119, 120, and AVP receptor antagonists (VRAs) have also been shown to be a potential treatment for COVID-19 by alleviating AVP-mediated hyponatremia 121.